SAN DIEGO, April 15, 2008 (PRIME NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, announced today that milatuzumab, its humanized anti-CD74 antibody, showed in animal models promising therapeutic activity for multiple myeloma when used alone or in combination with bortezomib and lenalidomide in cell culture systems. Both of these drugs are approved for the treatment of multiple myeloma.
